Anneke C. J. Ammerlaan

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Erica Brivio, Franco Locatelli, Marta López‐Yurda et al. · Blood · 2020 · 88 citations · Full text

Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome

Anneke C. J. Ammerlaan, Abdelhay Ararou, M.P.W.A. Houben et al. · British Journal of Cancer · 2007 · 74 citations · Full text

Developmental Biology, Somatic Variant, Mendelian Disorder +13

Localization of a putative low‐penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling‐path genomic microarray

Anneke C. J. Ammerlaan, Cecilia de Bustos, Abdelhay Ararou et al. · Genes Chromosomes and Cancer · 2005 · 28 citations

Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan et al. · Haematologica · 2024 · 17 citations · Full text

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Erica Brivio, Franco Locatelli, Adriana Thano et al. · Blood · 2020 · 16 citations